152 related articles for article (PubMed ID: 38777312)
21. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T;
Clin Exp Nephrol; 2018 Apr; 22(2):426-436. PubMed ID: 28836058
[TBL] [Abstract][Full Text] [Related]
22. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].
Bellasi A; Cozzolino M; Malberti F; Cancarini G; Esposito C; Genderini A; Guastoni CM; Ondei P; Pontoriero G; Teatini U; Vezzoli G; Messa P; Locatelli F
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786181
[TBL] [Abstract][Full Text] [Related]
23. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
Friedl C; Zitt E
Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
[TBL] [Abstract][Full Text] [Related]
24. Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease.
Newman CL; Tian N; Hammond MA; Wallace JM; Brown DM; Chen NX; Moe SM; Allen MR
Am J Nephrol; 2016; 43(1):20-31. PubMed ID: 26881752
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
Ota M; Takahata M; Shimizu T; Kanehira Y; Kimura-Suda H; Kameda Y; Hamano H; Hiratsuka S; Sato D; Iwasaki N
Osteoporos Int; 2017 Apr; 28(4):1481-1490. PubMed ID: 27933339
[TBL] [Abstract][Full Text] [Related]
26. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
27. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.
Cozzolino M; Galassi A; Conte F; Mangano M; Di Lullo L; Bellasi A
Ther Clin Risk Manag; 2017; 13():679-689. PubMed ID: 28615947
[TBL] [Abstract][Full Text] [Related]
28. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
Khan BA; Qu X; Hua Y; Javaid MM
Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
[TBL] [Abstract][Full Text] [Related]
29. Etelcalcetide for the treatment of secondary hyperparathyroidism.
Hamano N; Komaba H; Fukagawa M
Expert Opin Pharmacother; 2017 Apr; 18(5):529-534. PubMed ID: 28277829
[TBL] [Abstract][Full Text] [Related]
30. Etelcalcetide: First Global Approval.
Blair HA
Drugs; 2016 Dec; 76(18):1787-1792. PubMed ID: 27900648
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor, in vitro and in vivo.
Goto M; Nishimura G; Sato H; Yamaguchi Y; Morimoto N; Hashimoto H; Takahashi N
Eur J Pharmacol; 2023 Oct; 956():175936. PubMed ID: 37541363
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
[TBL] [Abstract][Full Text] [Related]
33. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
34. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
36. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration.
Díaz-Tocados JM; Rodríguez-Ortiz ME; Almadén Y; Pineda C; Martínez-Moreno JM; Herencia C; Vergara N; Pendón-Ruiz de Mier MV; Santamaría R; Rodelo-Haad C; Casado-Díaz A; Lorenzo V; Carvalho C; Frazão JM; Felsenfeld AJ; Richards WG; Aguilera-Tejero E; Rodríguez M; López I; Muñoz-Castañeda JR
Kidney Int; 2019 May; 95(5):1064-1078. PubMed ID: 30878213
[TBL] [Abstract][Full Text] [Related]
37. Pharmaceutical Management of Secondary Hyperparathyroidism and the Role of Surgery: A 5-Year Retrospective Study.
Sevva C; Divanis D; Tsinari A; Grammenos P; Laskou S; Mantalobas S; Paschou E; Magra V; Kopsidas P; Kesisoglou I; Liakopoulos V; Sapalidis K
Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38792994
[No Abstract] [Full Text] [Related]
38. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
[TBL] [Abstract][Full Text] [Related]
39. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
Eidman KE; Wetmore JB
Semin Dial; 2018 Sep; 31(5):440-444. PubMed ID: 30009474
[TBL] [Abstract][Full Text] [Related]
40. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia.
Ishii H; Wada M; Furuya Y; Nagano N; Nemeth EF; Fox J
Bone; 2000 Feb; 26(2):175-82. PubMed ID: 10678413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
